• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IFNL4 Gene Record

  • Summary
  • Interactions
  • Claims
  • IFNL4 101180976

    Alternate Names:

    101180976
    INTERFERON LAMBDA 4 (GENE/PSEUDOGENE)
    IFNL4
    IFNAN
    615090
    44480
    ENSG00000272395
    OTTHUMG00000185299
    PA166049147

    Gene Info:

    Gene Biotype POLYMORPHIC_PSEUDOGENE
    (0 More Sources)

    Gene Categories: Category Details

    Publications:

    Khan AJ et al., 2019, Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy., J Med Virol
    Hézode C et al., 2015, Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study., Gut
    D'Offizi G et al., 2017, Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection., New Microbiol
    Mori N et al., 2017, IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C., Hepatol Res
    Manns M et al., 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet
    Forns X et al., 2014, Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial., Gastroenterology
    Poordad F et al., 2012, Factors that predict response of patients with hepatitis C virus infection to boceprevir., Gastroenterology
    Pedergnana V et al., 2019, Impact of <i>IFNL4</i> Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients., J Interferon Cytokine Res
    Backus LI et al., 2018, Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals., Diagn Microbiol Infect Dis
    Ramamurthy N et al., 2018, Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C., Hepatology
    O'Brien TR et al., 2017, IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir., Gastroenterology
    O'Brien TR et al., 2017, Race or genetic makeup for hepatitis C virus treatment decisions?, Hepatology
    Akuta N et al., 2017, Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan., J Med Virol
    O'Brien TR et al., 2014, Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C., Open Forum Infect Dis
    Zeuzem S et al., 2013, Faldaprevir and deleobuvir for HCV genotype 1 infection., N Engl J Med
    Tsubota A et al., 2014, Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b., J Gastroenterol Hepatol
    Pol S et al., 2013, Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure., J Hepatol
    Suzuki F et al., 2011, Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir., Hepatology
    Akuta N et al., 2010, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin., Hepatology
    El-Khazragy N et al., 2018, IL-28β gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients., J Cell Biochem
    Sakhaee F et al., 2017, The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection., Infect Genet Evol
    Asnavandi M et al., 2017, EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C., Genes Immun
    Gauthiez E et al., 2017, A systematic review and meta-analysis of HCV clearance., Liver Int
    Kamal AM et al., 2016, Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection., Rom J Morphol Embryol
    Sedighimehr P et al., 2017, IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C., Arch Virol
    Ranjan P et al., 2016, Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent., Indian J Med Microbiol
    Mansoor S et al., 2016, Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?, J Gen Virol
    El-Bendary M et al., 2015, Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4., Hepatogastroenterology
    Schwarz KB et al., 2016, Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C., J Pediatr Gastroenterol Nutr
    Holmes JA et al., 2015, The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3., Aliment Pharmacol Ther
    Nadia K et al., 2015, The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C., Gene
    Cariani E et al., 2016, Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis., Pharmacogenomics J
    Terczyńska-Dyla E et al., 2014, Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes., Nat Commun
    Eslam M et al., 2014, IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection., J Hepatol
    Covolo L et al., 2014, The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection., Aliment Pharmacol Ther
    Ragheb MM et al., 2014, Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4., Liver Int
    Franco S et al., 2014, IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients., AIDS
    Piluso A et al., 2013, Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study., J Viral Hepat
    Stenkvist J et al., 2013, HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism., J Viral Hepat
    Luo Y et al., 2013, Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis., Gene
    Riva E et al., 2012, Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients., J Viral Hepat
    Kobayashi M et al., 2012, Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus., J Gastroenterol
    Antaki N et al., 2012, IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5., Gut
    Lopez-Rodriguez R et al., 2011, Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C., Clin Pharmacol Ther
    Asselah T et al., 2012, IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C., J Hepatol
    Ridruejo E et al., 2011, Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin., Ann Hepatol
    Lyoo K et al., 2011, Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin., J Clin Virol
    Giannini EG et al., 2011, IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin., Aliment Pharmacol Ther
    Lindh M et al., 2011, Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus., J Infect Dis
    Pineda JA et al., 2011, Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients., AIDS
    Labarga P et al., 2011, Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse., AIDS
    Coto-Llerena M et al., 2011, Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation., Am J Transplant
    Liao XW et al., 2011, Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population., Antivir Ther
    Moghaddam A et al., 2011, IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection., Hepatology
    Scherzer TM et al., 2011, Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin., J Hepatol
    Sarrazin C et al., 2011, Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients., J Hepatol
    Hayes CN et al., 2011, HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut
    Medrano J et al., 2010, Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV., Clin Infect Dis
    Pineda JA et al., 2010, Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus., Clin Infect Dis
    Stättermayer AF et al., 2011, Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C., Clin Gastroenterol Hepatol
    Mangia A et al., 2010, An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response., Gastroenterology
    Montes-Cano MA et al., 2010, Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes., Hepatology
    Thompson AJ et al., 2010, Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus., Gastroenterology
    Ge D et al., 2009, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance., Nature
  • SOFOSBUVIR   IFNL4

    Interaction Score: 25.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31260374 30431653 29866411 29534310 29107709 28100007 27357737 25734178


    Sources:
    PharmGKB

  • LEDIPASVIR   IFNL4

    Interaction Score: 11.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28100007 27357737 25734178


    Sources:
    PharmGKB

  • RIBAVIRIN   IFNL4

    Interaction Score: 9.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30450628 28739427 28703131 28261910 28072888 27833958 27714501 27514956 27498543 27027531 26902034 26284539 26032235 25958342 25918016 25534433 25080450 24907224 24768758 24602923 24308755 24117654 24102823 24072198 23490377 23383658 23321318 23142377 22863269 22626609 22438096 22345656 21993426 21951981 21911885 21907615 21726252 21606533 21572301 21537116 21466653 21447862 21374656 21246582 21145807 21112657 21068134 20964522 20804372 20728570 20648473 20621700 20578254 20399780 19684573


    Sources:
    PharmGKB

  • DACLATASVIR   IFNL4

    Interaction Score: 8.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30431653 25080450


    Sources:
    PharmGKB

  • TELAPREVIR   IFNL4

    Interaction Score: 7.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24117654 23321318 21246582 20648473


    Sources:
    PharmGKB

  • VOXILAPREVIR   IFNL4

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29107709


    Sources:
    PharmGKB

  • FALDAPREVIR   IFNL4

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23944300


    Sources:
    PharmGKB

  • DELEOBUVIR   IFNL4

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23944300


    Sources:
    PharmGKB

  • VELPATASVIR   IFNL4

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29107709


    Sources:
    PharmGKB

  • SIMEPREVIR   IFNL4

    Interaction Score: 3.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28072888 27027531 24907224 24602923


    Sources:
    PharmGKB

  • BOCEPREVIR   IFNL4

    Interaction Score: 1.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22626609


    Sources:
    PharmGKB

  • Ensembl: ENSG00000272395

    • Version: 101_38

    Alternate Names:
    IFNL4 Ensembl Gene Name

    Gene Info:
    Gene Biotype POLYMORPHIC_PSEUDOGENE

    Publications:

  • PharmGKB: IFNL4

    • Version: 18-August-2020

    Alternate Names:
    PA166049147 PharmGKB ID

    Gene Info:

    Publications:
    Pedergnana V et al., 2019, Impact of <i>IFNL4</i> Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients., J Interferon Cytokine Res
    Backus LI et al., 2018, Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals., Diagn Microbiol Infect Dis
    Kobayashi M et al., 2012, Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus., J Gastroenterol

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21